Aug 16 (Reuters) - Seagen said on Wednesday its cancer therapy in combination with Roche's Kadcyla helped control disease progression in a late-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
4,264 INR | +1.52% | +2.70% | 2.3B | ||
2,743 PTS | +2.11% | +3.03% | - | ||
219.8 CHF | -0.61% | -4.31% | 196B | ||
1st Jan change | Capi. | |
---|---|---|
+1.77% | 42.86B | |
+46.00% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |